Minagene's test utilizes targeted next-generation sequencing and array-based platforms to comprehensively detect somatic mutations, chromosomal rearrangements, and gene expression signatures in leukemia, lymphoma and myeloma specimens.



DNA and RNA are extracted from bone marrow, peripheral blood or tissue samples and processed for hybrid capture-based targeted sequencing of over 300 genes recurrently implicated in hematological cancers. Custom FISH/aCGH panels interrogate recurring translocations.

Key Highlights of Minagene’s Molecular Testing for Hematological Malignancies

Key Highlights of Minagene’s Molecular Testing for Hematological Malignancies

-Establishes definitive diagnoses for ambiguous morphologies

-Determines prognostic risk stratification and subtype classification

-Identifies targets for specific small molecule inhibitors and immunotherapies

-Monitors for minimal residual disease during and after treatment

-Features a CLIA-certified, CAP-accredited laboratory

By applying a multimodal genomic approach, clinicians can optimize therapeutic strategies from diagnosis through remission monitoring. Comprehensive mutational profiling assists clinical decision-making at all stages of care.

When to Consider Minagene’s Molecular Testing for Hematological Malignancies

Physicians should order Minagene’s molecular testing at initial workup of suspected hematological cancers as well as during surveillance and relapse to elucidate resistance mechanisms, guide clinical trial selection, and personalize management.


Minagene's panel utilizes hybrid capture-based next-generation sequencing to simultaneously evaluate over 500 cancer-related genes from solid tumor specimens. This identifies clinically relevant genomic alterations to guide targeted therapy selection.


Tumor DNA

Tumor DNA undergoes library preparation prior to enrichment of all coding exons across key oncogenes and tumor suppressors. Paired formalin-fixed paraffin-embedded and frozen tissue is supported. Whole exome sequencing is available based on indications.

Key Highlights of

Minagene’s NIPT

1. Comprehensive Fetal Genome Analysis:

-Interrogates both common and rare driver mutations

-Detects microsatellite instability and tumor mutational burden

-Determines homologous recombination deficiency status

-Identifies comprehensive genomic profiles

-Supports enrollment in matched clinical trials

By applying an unbiased genomic approach, clinicians gain a thorough understanding of pathogenic alterations to maximize treatment effectiveness through precision medicine paradigms.

When to Consider Minagene’s Comprehensive Tumor Gene Panel

Physicians should order Minagene's comprehensive panel for advanced solid tumors, particularly where standard therapies have failed, to guide selection of matched targeted agents and immunotherapies.


Minagene's proprietary gastrointestinal pathogen panel utilizes multiplex PCR and next-generation sequencing to simultaneously detect over 30 bacterial, viral and parasitic organisms associated with acute and chronic diarrhea.


Stool specimens

Stool specimens are treated with a lysis buffer and nucleic acid is extracted. Hypervariable regions are amplified using tiled primers barcoded for each pathogen. Sequencing on the Illumina platform at >10,000x coverage allows for identification of variants associated with antimicrobial resistance.

Key Highlights

Key Highlights

-Identifies causative agents missed by conventional assays

-Screens for emerging enteric pathogens like Cyclospora

-Assesses antibiotic resistance of detected bacteria

-Provides results within 5 days to guide targeted therapy

-Offers cost savings compared to sequential single-target testing

With its unparalleled breadth and speed, Minagene’s stool panel streamlines the diagnostic evaluation of gastroenteritis. Genome-resolved pathogen data assists clinical decision-making and public health monitoring of infectious outbreaks.

When to Consider Minagene’s Gastrointestinal Pathogen Test

This comprehensive test is recommended for patients with severe or prolonged diarrhea, particularly in transplant, oncology or malnourished populations where opportunistic infections necessitate rapid diagnosis and isolation.


Minagene's proprietary SES protocol concurrently isolates and
identifies causative organisms from bilateral ocular swabs, streamlining diagnosis of bacterial conjunctivitis, blepharitis,
keratitis and endophthalmitis. Deep sequencing with
bioinformatic analyses achieve comprehensive pathogen
detection from a single specimen.


The Syndrome Evaluation System

The Syndrome Evaluation System (SES) is a patented technology used for rapid multiplex amplification and accurate identification of virulence-associated genes of causative agents or organisms. This advanced platform surpasses conventional diagnostic tests by providing fast and precise results, especially when organisms are challenging to cultivate or locate. Currently available diagnostic technologies for detecting infections are inadequate, often failing to detect early stages of illness and delaying specific therapy in critical cases, which can lead to functional loss or even loss of life.

The SES amplifies genes

The SES amplifies genes, enhancing the sensitivity of the test. The re-naturation of the amplified signature gene to its chemically identified complementary gene sequence on the SES further improves accuracy.

Key Highlights of Minagene's Eye Infections Test

Higher Accuracy

Detects a greater number of cases compared to conventional methods

Reduction in Testing and Investigations

Avoids the need for multiple testing and unnecessary investigations, leading to cost savings.
Reduces the duration of stay in the intensive care unit (ICU) and associated costs.

Comprehensive Pathogen Detection

– Detects DNA of various pathogens, including fungi, viruses, parasites, and bacteria, in a single test.

-Capable of detecting both unimicrobial and polymicrobial infections.

Efficient Rule-in or Rule-out

Helps in confirming or excluding the presence of infections

Your compare list